116 related articles for article (PubMed ID: 22688785)
1. Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib.
Szmit S; Zaborowska M; Waśko-Grabowska A; Żołnierek J; Nurzyński P; Filipiak KJ; Opolski G; Szczylik C
Kidney Blood Press Res; 2012; 35(6):468-76. PubMed ID: 22688785
[TBL] [Abstract][Full Text] [Related]
2. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
3. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.
Ferté C; Koscielny S; Albiges L; Rocher L; Soria JC; Iacovelli R; Loriot Y; Fizazi K; Escudier B
Eur Urol; 2014 Apr; 65(4):713-20. PubMed ID: 23993162
[TBL] [Abstract][Full Text] [Related]
4. Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines.
Szmit S; Langiewicz P; Złnierek J; Nurzyński P; Zaborowska M; Filipiak KJ; Opolski G; Szczylik C
Kidney Blood Press Res; 2012; 35(1):18-25. PubMed ID: 21849795
[TBL] [Abstract][Full Text] [Related]
5. Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib.
Nakano K; Komatsu K; Kubo T; Natsui S; Nukui A; Kurokawa S; Kobayashi M; Morita T
Jpn J Clin Oncol; 2013 Oct; 43(10):1023-9. PubMed ID: 23956442
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study.
Kim SH; Kim S; Nam BH; Lee SE; Kim CS; Seo IY; Kim TN; Hong SH; Kwon TG; Seo SI; Joo KJ; Song K; Kwak C; Chung J
PLoS One; 2015; 10(8):e0135165. PubMed ID: 26308612
[TBL] [Abstract][Full Text] [Related]
7. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib-induced tuberculosis reactivation.
Teo M; O'Connor TM; O'Reilly SP; Power DG
Onkologie; 2012; 35(9):514-6. PubMed ID: 23007150
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis.
Omae K; Kondo T; Kennoki T; Takagi T; Iizuka J; Kobayashi H; Hashimoto Y; Tanabe K
Int J Clin Oncol; 2016 Feb; 21(1):126-32. PubMed ID: 26163345
[TBL] [Abstract][Full Text] [Related]
10. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.
Kusuda Y; Miyake H; Behnsawy HM; Fukuhara T; Inoue TA; Fujisawa M
Urol Oncol; 2013 Jan; 31(1):42-50. PubMed ID: 21396851
[TBL] [Abstract][Full Text] [Related]
11. Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib.
Shin SY; Lee YJ
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):837-46. PubMed ID: 24075093
[TBL] [Abstract][Full Text] [Related]
12. c-KIT: potential predictive factor for the efficacy of sorafenib in metastatic renal cell carcinoma with sarcomatoid feature.
Zhang HL; Zhu Y; Qin XJ; Wang CF; Yao XD; Zhang SL; Dai B; Zhu YP; Shi GH; Ye DW
Clin Genitourin Cancer; 2013 Jun; 11(2):134-40. PubMed ID: 23058498
[TBL] [Abstract][Full Text] [Related]
13. Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib.
Kashima T; Ohno Y; Tachibana M
Int J Urol; 2012 Nov; 19(11):1041-2. PubMed ID: 22788573
[No Abstract] [Full Text] [Related]
14. Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis.
Li Y; Li S; Zhu Y; Liang X; Meng H; Chen J; Zhang D; Guo H; Shi B
J Clin Hypertens (Greenwich); 2014 Mar; 16(3):177-85. PubMed ID: 24621095
[TBL] [Abstract][Full Text] [Related]
15. Relationship of pathologic factors to efficacy of sorafenib treatment in patients with metastatic clear cell renal cell carcinoma.
Araki H; Tsuzuki T; Kimura T; Tanaka K; Yamada S; Sassa N; Yoshino Y; Hattori R; Gotoh M
Am J Clin Pathol; 2015 Apr; 143(4):492-9. PubMed ID: 25780000
[TBL] [Abstract][Full Text] [Related]
16. Risk of Hypertension With Sorafenib Use in Patients With Cancer: A Meta-Analysis From 20,494 Patients.
Yang X; Pan X; Cheng X; Kuang Y; Cheng Y
Am J Ther; 2017; 24(1):e81-e101. PubMed ID: 26322676
[TBL] [Abstract][Full Text] [Related]
17. Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review.
Leonetti A; Bersanelli M; Castagneto B; Masini C; Di Meglio G; Pellegrino B; Buti S
Clin Genitourin Cancer; 2016 Aug; 14(4):277-83. PubMed ID: 26899142
[TBL] [Abstract][Full Text] [Related]
18. Management of sorafenib-related adverse events: a clinician's perspective.
Brose MS; Frenette CT; Keefe SM; Stein SM
Semin Oncol; 2014 Feb; 41 Suppl 2():S1-S16. PubMed ID: 24576654
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sorafenib in advanced renal cell cancer and validation of Heng criteria.
Joshi A; Ramaswamy A; Noronha V; Patil VM; Chandrasekharan A; Goel A; Sahu A; Sable N; Agrawal A; Menon S; Prabhash K
Indian J Cancer; 2016; 53(3):423-428. PubMed ID: 28244475
[TBL] [Abstract][Full Text] [Related]
20. Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib.
Zhang HL; Zhu Y; Wang CF; Yao XD; Zhang SL; Dai B; Shen YJ; Zhu YP; Shi GH; Ye DW
Int J Urol; 2011 Jun; 18(6):422-30. PubMed ID: 21481012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
